Santhera Publishes Annual Report 2022 Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day…
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) — Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”),…
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the…
CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (CARGO), a biotechnology…
CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (CARGO), a biotechnology…
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with…
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with…
Parexel Rated “Top CRO to Work With” in 2023 WCG CenterWatch Global Site Relationship Benchmark Survey for Second Straight Time
Company receives highest average rating across all 26 performance attributes out of 34 CROs included…
Parexel Rated “Top CRO to Work With” in 2023 WCG CenterWatch Global Site Relationship Benchmark Survey for Second Straight Time
Company receives highest average rating across all 26 performance attributes out of 34 CROs included…
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Once granted, this patent will provide intellectual property protection until December 2040, and may qualify…
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Once granted, this patent will provide intellectual property protection until December 2040, and may qualify…
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical…
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical…
Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors
REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company…
Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors
REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company…
COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer
She will remain a member of the COMPASS Pathways Board of Directors LONDON, May 31,…
COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer
She will remain a member of the COMPASS Pathways Board of Directors LONDON, May 31,…
Evaxion Announces Business Update and First Quarter 2023 Financial Results
Full read-out of the Phase 1/2a trial of EVX-02 in 10 patients with completely resected…
Evaxion Announces Business Update and First Quarter 2023 Financial Results
Full read-out of the Phase 1/2a trial of EVX-02 in 10 patients with completely resected…
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates
– TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily…